Chinese pharma Hansoh Pharma (HKEX: 3692) has secured approval from China’s National Medical Products Administration for an ...
SurvivorNet on MSN
Targeted therapy in a shot: New approval for EGFR-mutated lung cancer can improve day-to-day life for patients
Rybrevant Faspro, the new subcutaneous version of amivantamab, was approved for patients with a specific form of lung cancer ...
The U.S. Food and Drug Administration has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and only subcutaneously administered therapy for patients with epidermal growth ...
In Brazil, the early detection of genetic alterations in lung cancer through liquid biopsies could be a valuable tool for ...
Combining TRT with EGFR-TKIs significantly improves PFS and OS in EGFR-mutated oligo-organ metastatic NSCLC patients compared to EGFR-TKIs alone. The study suggests personalized treatment approaches, ...
Dr Mark Kris breaks down the lazertinib-amivantamab data, noting that the combo shows benefit but fails to address key ...
Could a daily pill after chemoradiation keep lung cancer from returning? The News On 6 weekend team provides a comprehensive look at updated news events, a detailed and up-to-the-minute weather ...
The PD-1/L1 inhibitor class of drugs has vastly improved care for many patients with cancer, but some meds in the class have posted trial failures lately. At the American Society of Clinical ...
A daily pill called osimertinib (Tagrisso) is delivering far longer cancer control for adults with unresectable stage 3 EGFR-mutated non-small cell lung cancer after chemoradiation and is now ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback